Stay updated on Nivolumab±Ipilimumab in Ovarian & Clear Cell Carcinomas Clinical Trial
Sign up to get notified when there's something new on the Nivolumab±Ipilimumab in Ovarian & Clear Cell Carcinomas Clinical Trial page.

Latest updates to the Nivolumab±Ipilimumab in Ovarian & Clear Cell Carcinomas Clinical Trial page
- Check3 days agoChange DetectedRevision: v3.5.0 was added and v3.4.3 was removed as part of a version update. This appears to be a backend or UI update with no changes to the study information displayed on the page.SummaryDifference0.1%

- Check11 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check39 days agoChange DetectedAdded primary peritoneal carcinoma and fallopian tube cancer to the listed conditions, and introduced the Genetic and Rare Diseases Information Center as a new resource. Updated page revision to v3.4.2 and removed the prior funding-status notice (v3.4.1).SummaryDifference0.6%

- Check47 days agoChange DetectedThe page adds a site-wide government funding/status notice and updates the site revision from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check54 days agoChange DetectedAdded 'Show glossary' and updated footer labels, including 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and the revision note 'Revision: v3.4.0' (replacing v3.3.4). These changes do not modify core study data or essential information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check68 days agoChange DetectedThe page now displays Revision: v3.3.4, replacing Revision: v3.3.3; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Nivolumab±Ipilimumab in Ovarian & Clear Cell Carcinomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab±Ipilimumab in Ovarian & Clear Cell Carcinomas Clinical Trial page.